An investigation for investors in NASDAQ:ALXN shares over potential securities laws violations by Alexion Pharmaceuticals, Inc. and certain of its directors and officers in connection certain financial statements was announced.
Investors who purchased shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) concerning whether a series of statements by Alexion Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
New Haven, CT based Alexion Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of life-transforming therapeutic productsOn June 6, 2016, Alexion Pharmaceuticals, Inc announced topline results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in patients with refractory generalized myasthenia gravis.
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) declined from $155.78 per share on June 6, 2016 to $124.80.18 per share on June 17, 2016.
Those who purchased NASDAQ:ALXN shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com